Captopril suppresses Post-transplantation angiogenic activity in rat allograft coronary vessels

Journal of Heart and Lung Transplantation

Volumn 23, Issue 6, 2004, Pages 666-673

  Crawford, Susan E ^a,b   Mavroudis, Constantine ^a   Backer, Carl L ^a   Huang, Xuemei ^a   Mu, Yan ^a   Volpert, Olga V ^b   Stellmach, Veronica ^a   Pahl, Elfriede ^a   Huang, Lijun ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CAPTOPRIL; THROMBOCYTE ACTIVATING FACTOR; THROMBOSPONDIN 1; VASCULOTROPIN;

ANALYTIC METHOD; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORONARY ARTERY; CORONARY ARTERY DISEASE; CULTURE MEDIUM; DRUG EFFECT; FEMALE; GRAFT REJECTION; HEART DISEASE; HEART MUSCLE; HEART TRANSPLANTATION; LIPID BLOOD LEVEL; MALE; NONHUMAN; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; TREATMENT OUTCOME; UPREGULATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; CELL CULTURE TECHNIQUES; CELL MOVEMENT; CORNEA; CORONARY ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HEART TRANSPLANTATION; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; PLATELET ACTIVATING FACTOR; RATS; RATS, INBRED F344; RATS, INBRED LEW; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2642564296     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2003.07.010     Document Type: Article

References (41)

1. Bouck N., Stellmach V., Hsu S.C. How tumors become angiogenic. Adv Cancer Res. 69:1996;135-174
2. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364
3. Carmeliet P. Angiogenesis in health and disease. Nature Med. 9:2003;653-660
4. Ramos M.A., Kuzuya M., Esaki T., et al. Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 18:1998;1188-1196
5. Inoue M., Itoh H., Ueda M., et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions Possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 98:1998;2108-2116
6. Subbanagounder G., Leitinger N., Shih P.T., Faull K.F., Berliner J.A. Evidence that phospholipids oxidation products and/or platelet-activating factor play an important role in early atherogenesis In vitro and in vivo inhibition by WEB 2086. Circ Res. 85:1999;311-318
7. Billingham M.E. Histopathology of graft coronary disease. J Heart Lung Transplant. 11:(3Pt2):1992;S38-44
8. Silverstein R.L., Nachman R.L. Angiogenesis and atherosclerosis. The mandate broadens. Circulation. 100:1999;783-785
9. Bo W.J., Mercuri M., Tucker R., Bond M.G. The human carotid atherosclerotic plaque stimulates angiogenesis on the chick chorioallantoic membrane. Atherosclerosis. 94:1992;71-78
10. Shing Y., Folkman J., Haudenschild C., Lund D., Crum R., Klagsbrun M. Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Cell Biochem. 29:1985;275-287
11. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 359:1992;845-848
12. Volpert O.V., Stellmach V., Bouck N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat. 36:1995;119-126
13. Keck P.J., Hauser S.D., Krivi G., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1989;1309-1312
14. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 77:1999;527-543
15. Pepper M.S., Ferrara N., Orci L., Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 189:1992;824-831
16. Bernatchez P.N., Soker S., Sirois M.G. Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem. 274:1999;31047-31054
17. Sirois M.G., Edelman E.R. VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor. Am J Physiol. 272:(6Pt2):1997;H2746-2756
18. Neville R.F., Sidawy A.N. Myointimal hyperplasia Basic science and clinical considerations. Semin Vasc Surg. 11:1998;142-148
19. Moulton K.S., Heller E., Konerding M.A., Flynn E., Palinski W., Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 99:1999;1726-1732
20. Volpert O.V., Ward W.F., Lingen M.W., et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest. 98:1996;671-679
21. Prontera C., Mariani B., Rossi C., Poggi A., Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer. 81:1999;761-766
22. Kobayashi J., Crawford S.E., Backer C.L., et al. Captopril reduces graft coronary artery disease in a rat heterotopic transplant model. Circulation. 88:(5Pt2):1993;II286-290
23. Crawford S.E., Huang L., Hsueh W., et al. Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats Role of endogenous PAF and PAF-like compounds. J Heart Lung Transplant. 18:1999;470-477
24. National Institutes of Health. Guide for the care and use of laboratory animals. 1985;1-70 US Department of Health & Human Services, Bethesda, MD. NIH Pub No 86-23
25. Ono K., Lindsey E.S. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg. 57:1969;225-229
26. Gao S.Z., Schroeder J.S., Alderman E.L., et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation. 76:(5Pt2):1987;V56-61
27. Uretsky B.F., Murali S., Reddy P.S., et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 76:1987;827-834
28. Kriett J.M., Kaye M.P. The Registry of the International Society for Heart Transplantation Seventh official report - 1990. J Heart Transplant. 9:1990;323-330
29. Hosenpud J.D., Shipley G.D., Wagner C.R. Cardiac allograft vasculopathy Current concepts, recent developments, and future directions. J Heart Lung Transplant. 11:(1Pt1):1992;9-23
30. Backer C.L., Zales V.R., Idriss F.S., et al. Heart transplantation in neonates and in children. J Heart Lung Transplant. 11:(2Pt1):1992;311-319
31. Naftilan A.J., Pratt R.E., Dzau V.J. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 83:1989;1419-1424
32. Bell L., Madri J.A. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 137:1990;7-12
33. Gibbons G.H., Pratt R.E., Dzau V.J. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J Clin Invest. 90:1992;456-461
34. Molloy C.J., Taylor D.S., Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J Biol Chem. 268:1993;7338-7345
35. Powell J.S., Clozel J.P., Müller R.K., et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 245:1989;186-188
36. Scheidegger K.J., Wood J.M. Local application of angiotensin II to the rat carotid artery induces adventitial thickening. J Vasc Res. 34:1997;436-446
37. Gately S., Twardowski P., Stack M.S., et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA. 94:1997;10868-10872
38. Andrade S.P., Vieira L.B., Bakhle Y.S., Piper P.J. Effect of platelet activating factor (PAF) on the formation of blood vessels in subcutaneous implants in mice. J Lipid Mediat Cell Signal. 9:1994;117-121
39. Bussolino F., Arese M., Montrucchio G., et al. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest. 96:1995;940-952
40. Camussi G., Montrucchio G., Lupia E., et al. Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol. 154:1995;6492-6501
41. Soldi R., Sanavio F., Aglietta M., et al. Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p 125FAK) in human endothelial cells. Oncogene. 13:1996;515-525